Advertisement
UK markets close in 3 hours 34 minutes

  • FTSE 100

    8,237.03
    +31.92 (+0.39%)
     

  • FTSE 250

    20,456.73
    +75.68 (+0.37%)
     

  • AIM

    774.71
    -2.79 (-0.36%)
     

  • GBP/EUR

    1.1828
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2683
    -0.0038 (-0.30%)
     

  • Bitcoin GBP

    52,162.37
    +807.34 (+1.57%)
     

  • CMC Crypto 200

    1,376.73
    -5.93 (-0.43%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CRUDE OIL

    81.70
    +0.13 (+0.16%)
     

  • GOLD FUTURES

    2,354.30
    +7.40 (+0.32%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     

  • DAX

    18,155.28
    +87.37 (+0.48%)
     

  • CAC 40

    7,643.57
    +73.37 (+0.97%)
     
Money:

Best UK mortgage deals of the week

Average two-year mortgage deal is now around 6%

Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

Business Wire
·1-min read

– Presentation to be webcast on www.exelixis.com –

ALAMEDA, Calif., May 28, 2024--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m. ET / 3:20 p.m. CT / 1:20 p.m. PT in Chicago.

To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

ADVERTISEMENT

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528802316/en/

Contacts

Investors Contact:
Varant Shirvanian
Director, Investor Relations
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com

Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com